NOT FOR DISTRIBUTION
Header cover image

Market Cap

€23.8m

Last Updated

2021/05/15 16:21 UTC

Data Sources

Company Financials

Executive Summary

Lavipharm S.A. engages in the research, development, manufacturing, import, marketing, sales, wholesaling, and retailing of pharmaceutical, dermocosmetic, and healthcare products in Greece and internationally. More Details


Snowflake Analysis

Slightly overvalued with questionable track record.

Share Price & News

How has Lavipharm's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: LAVI is more volatile than 90% of Greek stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: LAVI's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Greek stocks.


Market Performance


7 Day Return

-9.5%

LAVI

0%

GR Pharmaceuticals

0%

GR Market


1 Year Return

76.5%

LAVI

0%

GR Pharmaceuticals

0%

GR Market

Return vs Industry: LAVI exceeded the Greek Pharmaceuticals industry which returned -2.7% over the past year.

Return vs Market: LAVI exceeded the Greek Market which returned -8.7% over the past year.


Shareholder returns

LAVIIndustryMarket
7 Day-9.5%0%0%
30 Day-19.7%0%0%
90 Day-3.7%0%0%
1 Year76.5%76.5%0%0%0%0%
3 Year130.7%130.7%0%0%0%0%
5 Year319.8%319.8%0%0%0%0%

Long-Term Price Volatility Vs. Market

How volatile is Lavipharm's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Lavipharm undervalued compared to its fair value and its price relative to the market?

10.99x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: LAVI (€0.47) is trading above our estimate of fair value (€0.13)

Significantly Below Fair Value: LAVI is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: LAVI is good value based on its PE Ratio (11x) compared to the European Pharmaceuticals industry average (24.3x).

PE vs Market: LAVI is good value based on its PE Ratio (11x) compared to the Greek market (19.2x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate LAVI's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: LAVI has negative assets, so we can't compare its PB Ratio to the XE Pharmaceuticals industry average.


Future Growth

How is Lavipharm forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Lavipharm has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Lavipharm performed over the past 5 years?

9.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: LAVI has high quality earnings.

Growing Profit Margin: LAVI's current net profit margins (5.8%) are lower than last year (15.9%).


Past Earnings Growth Analysis

Earnings Trend: LAVI has become profitable over the past 5 years, growing earnings by 9.8% per year.

Accelerating Growth: LAVI's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: LAVI had negative earnings growth (-59.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (6.9%).


Return on Equity

High ROE: LAVI's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Financial Health

How is Lavipharm's financial position?


Financial Position Analysis

Short Term Liabilities: LAVI has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: LAVI has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: LAVI has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: LAVI's has negative shareholder equity, so we do not need to check if its debt has reduced over time.

Debt Coverage: LAVI's debt is not well covered by operating cash flow (10.5%).

Interest Coverage: LAVI's interest payments on its debt are not well covered by EBIT (2.8x coverage).


Balance Sheet


Dividend

What is Lavipharm current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate LAVI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate LAVI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if LAVI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LAVI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of LAVI's dividend in 3 years as they are not forecast to pay a notable one for the Greek market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Lavipharm has no CEO, or we have no data on them.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Lavipharm S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Lavipharm S.A.
  • Ticker: LAVI
  • Exchange: ATSE
  • Founded: 1911
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €23.804m
  • Shares outstanding: 51.08m
  • Website: https://www.lavipharm.gr

Number of Employees


Location

  • Lavipharm S.A.
  • Agias Marinas Street
  • PO Box 59
  • Paiania
  • 190 02
  • Greece

Listings


Biography

Lavipharm S.A. engages in the research, development, manufacturing, import, marketing, sales, wholesaling, and retailing of pharmaceutical, dermocosmetic, and healthcare products in Greece and internationa...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/15 16:21
End of Day Share Price2021/05/14 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.